Driver mutations promote initiation and progression of cancer. Pharmacological treatment
can inhibit the action of the mutant protein; however, drug resistance almost invariably …

The molecular features that define clear cell renal cell carcinoma (ccRCC) initiation and
progression are being increasingly defined. The TRACERx Renal studies and others that …

Lung cancer is the leading cause of cancer-associated mortality worldwide. Here we
analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 …

Mutations in cancer-associated genes drive tumour outgrowth, but our knowledge of the
timing of driver mutations and subsequent clonal dynamics is limited,–. Here, using whole …

Clear cell renal cell carcinomas (ccRCCs) represent∼ 75% of RCC cases and account for
most RCC-associated deaths. Inter-and intratumoral heterogeneity (ITH) results in varying …

The functions of the tumor microenvironment (TME) are orchestrated by precise spatial
organization of specialized cells, yet little is known about the multicellular structures that …

PD-1 blockade has transformed the management of advanced clear cell renal cell
carcinoma (ccRCC), but the drivers and resistors of the PD-1 response remain incompletely …

Clinical and laboratory studies over recent decades have established branched evolution as
a feature of cancer. However, while grounded in somatic selection, several lines of evidence …

Renal cell carcinoma (RCC) is the most common type of kidney cancer and comprises
several subtypes with unique characteristics. The most common subtype (~ 70% of cases) is …

The observation and analysis of intra-tumour heterogeneity (ITH), particularly in genomic
studies, has advanced our understanding of the evolutionary forces that shape cancer …